tbuckley/cabot-search huggingface dataset:
Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort
Authors: Anna Molto, Sophie Tezenas du Montcel, Daniel Wendling, Maxime Dougados, Antoine Vanier, Laure Gossec
Journal: Annals of the Rheumatic Diseases (2016)

Background Disease activity may change over time in axial spondyloarthritis (axSpA). The objectives were to identify patterns of disease activity evolution in patients with early axSpA. Methods Patients from the prospective early axSpA cohort (DEvenir des Spondyloarthrites Indifférenciées Récentes (DESIR)) who fulfilled the Assessment in SpondyloArthritis Society (ASAS) criteria for axSpA at baseline and with at least three Ankylosing Spondylitis Disease Activity Score (ASDAS) values available over the 3 years of follow-up were analysed. Statistical analyses: trajectories were estimated by group-based trajectory modelling; predisposing baseline factors for such trajectories were identified by univariate and multivariable multinomial (logit) regression; work disability over time was compared between the trajectories by Cox hazard model. Results In all, 370 patients were analysed: mean disease duration was 1.6 (±0.9) years. The five distinct trajectories of disease activity over the 3 years were (t1) ‘persistent moderate disease activity’ (n=134 (36.2%)); (t2) ‘persistent inactive disease’ (n=66 (17.8%); (t3) ‘changing from very high disease activity to inactive disease’ ((n=29 (7.8%)); (t4) ‘persistent high disease activity’ (n=126 (34.1%)) and (t5) ‘persistent very high disease activity’ (n=15 (4.1%)). After adjustment for other characteristics, t2 was associated with a white-collar job (OR=2.6 (95% CI 1.0 to 6.7)) and t3 with male gender (OR=7.1 (1.6 to 32.2)), higher education level (OR=9.4 (1.4 to 63.4)) and peripheral joint involvement (OR=6.2 (1.23 to 31.32)). Patients from (t4) and (t5) were more often declared work disabled over follow-up (HR=5.2 (1.5 to 18.0) and HR=8.0 (1.3 to 47.9), respectively). Conclusions Trajectory modelling of disease activity was feasible in early axSpA: more than 30% patients (141/370) were in a trajectory with a persistent high disease activity. Persistent high disease activity trajectories were significantly associated with consequences on work. Trial registration number NCT01648907 .
AB0441 Effectiveness of Tocilizumab in Monotherapy in Patients with Rheumatoid Arthritis in Clinical Practice: Table 1
Authors: B. Magallares, E. Quesada-Masachs, M. Hernández, M. Lisbona, P. Moya, M. Moreno, V. Torrente-Segarra, D. Reina, J. Narváez, S. Marsal, R. Sanmartí, J. Calvet, J. Maymό, C. Díaz-Torné, A. Gόmez, H. Corominas, J. Nolla, A. Rodríguez de la Serna
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> There are few data about Tocilizumab (TCZ) in monotherapy effectiveness in clinical practice conditions <h3>Objectives</h3> To analyze the effectiveness TCZ monotherapy at medium/long term in clinical practice <h3>Methods</h3> Observational, retrospective, multicenter, 2-year study of RA patients on TCZ monotherapy.We recorded: demographic and clinical data (duration of RA, RF and CCP antibodies, previous treatments and reason for its discontinuation); At baseline and at 3, 6, 9, 12, 18 and 24 months:RA activity (DAS-28 ESR index, TJC, SJC, ESR, CRP and % of patients in Remission or Low Disease Activity (LDA). Adverse effects were also recorded <h3>Results</h3> 123 patients were included, with a mean age of 57.7±12.5 years and 85.4% females. Mean disease duration of 14.4±12.0 y; 67.5% and 5993% were RF and anti-CCP positive. 98.4% had previously received conventional DMARD (2 DMARDs: 30.9% and ≥3 DMARDs: 38.2%), reasons for DMARD discontinuation were inefficacy (26%), adverse events (58.5), patient decision (8.9%) and other reasons (4.1%). 13% had not received prior biological DMARDs; 34.1% had received 1; 20.3% 2; 16.3% 3; 8.9% 4 and 6.5% ≥5) A relationship between Remission/LDA and disease duration and reason for discontinuation of prior conventional DMARD was not found. An association among the number of previous biological treatments and a low disease activity at 6 m (p&lt;0.017), 9m (p&lt;0.025) and 12m (p&lt;0.028) was observed. 41 patients discontinued treatment (33.3%): 17due to inefficacy, 13 due to AE, 4 because of patient decision and 7 due to other reasons. No association between discontinuation of TCZ and duration of disease or number of previous biological DMARDs was found. <h3>Conclusions</h3> In our experience, TCZ monotherapy is effective at medium/long term regardless of the duration of the disease and previous treatments, maintaining a high retention rate <h3>Disclosure of Interest</h3> None declared
A comparison of the Diagnostic Interview Schedule and clinical diagnosis
Authors: H P Erdman, M H Klein, J H Greist, S M Bass, J K Bires, P E Machtinger
Journal: American Journal of Psychiatry (1987)

The Diagnostic Interview Schedule (DIS) was administered to 220 psychiatric patients by lay interviewers. Kappas for agreement between DIS and chart diagnoses ranged from .39 to -.03 and averaged .14 for 13 diagnostic categories. Agreement was best for affective, obsessive-compulsive, and schizophrenic disorders and was poorest for phobias where patients overemphasized fears. The authors suggest that clinician evaluation of information collected by the DIS is important, especially in diagnosing individual cases.
Foundation funding and psychiatric research
Authors: D Kim, H A Pincus, T Fine
Journal: American Journal of Psychiatry (1988)

Support for psychiatric research is limited to a relatively small number of funding sources. Foundations--nonprofit entities that support a variety of social, medical, educational, and other activities--are a potentially important source. The authors describe the role and structure of foundations, discuss historical trends in foundation support for research in mental illness, and present the results of a study of the extent to which foundations support mental health research. The results of this study confirm the paucity of foundation support for mental health research but show important differences and similarities among the foundations that support research in this field.
Digitalis intoxication misdiagnosed as depression by primary care physicians
Authors: F S Wamboldt, J W Jefferson, M Z Wamboldt
Journal: American Journal of Psychiatry (1986)

Three cases are described in which digitalis intoxication was misdiagnosed as depression by primary care physicians. The authors discuss the potentially life-threatening consequences of such a misdiagnosis, guidelines for an accurate diagnosis, and the implications for medical education.
Potential HIV exposure in psychiatrically hospitalized adolescent girls
Authors: D G Baker, D Mossman
Journal: American Journal of Psychiatry (1991)

The authors surveyed 23 psychiatrically hospitalized adolescent girls regarding behavior that involves high risk of HIV infection. Over half (57%) of the girls reported high-risk sexual activities; these girls were more likely to have sexually transmitted diseases, substantial drug abuse histories, and diagnoses of conduct disorder.
Value of the DST for predicting response of patients with major depression to hospitalization and desipramine
Authors: J C Nelson, C M Mazure, P I Jatlow
Journal: American Journal of Psychiatry (1990)

The authors examined the value of the dexamethasone suppression test (DST) for predicting response of patients with unipolar, nonpsychotic major depression to 1 week of hospitalization without antidepressant drugs and to a 4-week trial of desipramine at a fixed plasma level. The rates of response to hospitalization without drug treatment (defined as a score of 12 or less on the Hamilton Rating Scale for Depression) were not significantly different for the patients with a positive DST and those with a negative DST. This finding differs from those of prior studies of the DST and response to placebo. The responses of the DST-positive and DST-negative patients to desipramine also did not differ, a finding that replicates those in some prior reports.
Transcolonoscopic Extraperitoneal Cecostomy
Authors: A J Ganc, A J Netto, A C Morrell, H Plapler, J C Ardengh
Journal: Endoscopy (1988)

The authors propose a new technique of decompression of the colon consisting in percutaneous cecostomy with previous extraperitonization of the cecum under colonoscopic orientation. The technique permits decompression of the entire colon through the insertion of a ceco-anal multiperforated Levine tube on withdrawing the colonoscope. It is a new therapeutic choice for the treatment of the Ogilvie syndrome, toxic megacolon and other morbid entities, which may permit the performance of the procedure and require decompression of the colon, which proved to be extremely effective in the treatment of a patient with the Ogilvie syndrome.
Surveillance of giardiasis in Northwest England 1996-2006: impact of an enzyme immunoassay test
Authors: H Ellam, N Q Verlander, K Lamden, J S Cheesbrough, C A Durband, S James
Journal: Eurosurveillance (2008)

The incidence of giardiasis in Central Lancashire increased following the introduction of a sensitive enzyme immunoassay diagnostic test in November 2002. We compared the epidemiological trends for 1996-2006 in Central Lancashire with a control area which used a standard wet preparation diagnostic method throughout. Poisson regression modelling was used to investigate trends in giardiasis before and after the introduction of the test. In the control area, incidence of giardiasis was four per 100,000 in 2005. In contrast, in Central Lancashire, the rates increased in temporal association with the introduction of the enzyme immunoassay test from 10.1 per 100,000 population in 2002 to 33.6 per 100,000 in 2006. The increase in giardiasis was unexplained by local factors including travel, outbreaks or sampling trends. The increase in giardiasis occurred in all age groups except for males aged 0-14 years and was most marked in males aged 25-44 years. The relative risk for trend post-test introduction in Central Lancashire was 1.11 (95% CI, 1.01-1.23). This suggests that the increase in giardiasis following the introduction of the sensitive enzyme immunoassay test was at least in part due to improved detection. There appears to be considerable under-diagnosis of giardiasis, particularly in adults. Additional research is required to evaluate the enzyme immunoassay test more widely. The test may assist in standardisation of diagnostic methods for giardiasis and enable more accurate estimation of disease burden and transmission routes.
Immunohistochemical analysis of c-kit (CD117) expression in solid tumors
Authors: R. Weber, M. Medinger, M. Kleinschmidt, D. Filipovic, H. E. Schaefer, C. Unger
Journal: Journal of Clinical Oncology (2004)

9642 Background: c-kit functions as a tyrosine kinase receptor which becomes activated upon binding of its ligand SCF (stem-cell factor). Imatinib (Gleevec) is a small molecule known to inhibit the c-kit proto-oncogene, BCR-ABL tyrosine kinase and platelet-derived growth factor (PDGF) receptor. Imatinib has gained therapeutic relevance in the treatment of Chronic Myeloid Leukemia and has shown remarkable efficacy in the treatment of gastrointestinal stromal tumors (GIST). Because functions of Imatinib rely on the presence of mutated and activated c-kit, we studied the expression pattern for c-kit in a panel of different primary solid tumor sample. Methods: Paraffin-embedded tumor tissues from 295 patients were analyzed, including 51 breast cancer samples, 49 colorectal cancer, 21 renal cell carcinoma, 19 ovarian cancer, 18 sarcoma and 137 others. On these tumor samples c-kit expression was immunohistochemically evaluated using a polyclonal rabbit anti-human c-kit antibody (DAKO®). Staining results for each sample were scored from 0 (negative), + (weak), ++ (medium), +++ (strong). Results: c-kit immunopositivity was found in 37/295 (13%) cases, whereas 258/295 (87%) cases were negative. A strong expression of c-kit was found in 1 sarcoma, 1 GIST (gastrointestinal stromal tumor), 1 seminoma and 1 carcinoid. Of all 37 cases positive for c-kit, a strong expression was found in 4/37 (11%), c-kit medium expression in 11/37 (30%) and c-kit low reactivity was found in 22/37 (59%). Conclusions: Expression of c-kit was found in tumor samples with varying intensities. Out of 295 samples tested, 4 tumor samples (namely GIST, sarcoma, seminoma and carcinoid) showed high expression of c-kit. Analysis of the immunohistological results for c-kit expression lead to the definition of a scoring system in our hands: negative to strong c-kit expressing tumor samples. Further validation and correlation with clinical outcomes should lead to the definition of the relevance of this immunohistological classification. In addition, molecular analysis of c-kit mutations and activation status of the receptor should further help to predict the therapeutic implication of Imatinib in tumor patients. No significant financial relationships to disclose.
FRI0197 Role of Arginase in a Cellular and Murine Model of Endochondral Ossification
Authors: C. Prati, F. Cailotto, K. Heritage, D. Wendling, R. Lories
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Arginase is a metallo-enzyme which hydrolyzes L-arginine to urea and L-ornithine which is a precursor of proline and polyamines, compounds involved in cell proliferation and collagen synthesis. It has been reported that the expression and activity of arginase could be increased by inflammatory trigger. Our objectives were to study the role of arginase in a cellular model of endochondral ossification and then evaluate the effect of in vivo inhibition of arginase in a murine model of arthritis with post inflammatory new bone formation. <h3>Methods</h3> In vitro, we used the ATDC5 cell culture model during 21 days to study the different stages of the chondrocyte differentiation. We performed on micromass on day 1, 7, 14 and D21, RNA analysis by qPCR, staining by alcian blue, alizarin and sirius red and aWestern blot analysis. We studied in this model the effect of overexpression of arginase II using plasmid pcDNA 3.1, the effect of treatment with norNOHA, a selective inhibitor of arginase, and the behavior of ATDC5 KO for arginase II gene, using a plasmid GIPZ. In vivo, we used the model of arthritis induced by anti-type II collagen antibodies in male mice DBA1 aged of 8 weeks. An in vivo microCT of tarsus was performed before immunization. Animals were divided into 3 groups of 12: untreated (PBS injected), treated with norNOHA 10mg/kg/day and norNOHA 40mg/kg/day ip. Treatment was started two weeks after the beginning of clinical signs of arthritis and until sacrifice (20 days of treatment). A new microCT of tarsus was performed ex vivo with analysis of bone volumes and surfaces of a predefined area of tarsus. <h3>Results</h3> Stainings inform us that the overexpression of arginase II yielded micromass with greater chondrogenesis, RNA analysis demonstrates overexpression of aggrecan and collagen Xa. ERK1 protein appears to be inhibited by overexpression of arginase II in micromass J1, J7 and J14.In ATDC5 Arginase II KO, expression of collagen Xa, collagen II and aggrecan is decreased compared to control. Treatment with norNOHA did not change weight or clinical scoring of arthritis compared to the control group.In mice with clinical arthritis of tarsus (n=5 per group), the change in volume between the two microCT seems lower in treated groups compared to the control group (+0,23mm<sup>3</sup> norNOHA40; +0,5mm<sup>3</sup> norNOHA10 et +0,86mm<sup>3</sup> control group). <h3>Conclusions</h3> In ATDC5 model, overexpression of arginase induces an increase of chondrogenesis and inhibition in vivo of arginase in a murine model of arthritis, seems to decrease the volume of post inflammation bone formation. <h3>Acknowledgements</h3> Grant from Société Française de Rhumatologie and Conseil Regional de Franche Comté <h3>Disclosure of Interest</h3> None declared
Efficacy of systemic chemotherapy (CT) for the patients (pts) with unresectable liver metastasis (LM) of colorectal cancer (CRC)
Authors: K. Mera, A. Ohtsu, T. Doi, M. Muto, Y. Sano, S. Takahashi, S. Yoshida
Journal: Journal of Clinical Oncology (2006)

13567 Background: Surgical resection of colorectal LM is the only treatment which provides long-term survival for pts with advanced disease confined to the liver. However, most of LM are initially unresectable. The aim of this retrospective study was to evaluate the efficacy of systemic CT for the pts with initially unresectable LM from CRC. Methods: Subjects of this study were advanced CRC with unresectable LM treated by systemic CT at our institution between Aug ’92 and Dec ’03, and fulfilled the following criteria; Age ≤ 75, PS ≤ 2, histologically confirmed colorectal adenocarcinoma, no extrahepatic disease, no prior CT and no serious complication. Results: A total of 349 pts with metastatic CRC were managed by systemic CT between the period. Among these, there were 47 pts who met the recruitment criteria. Their characteristics were; male/female: 32/15, median age (range): 59 (34–75), PS 0/1/2: 33/12/2, primary tumor: colon/rectum: 26/21, sinchronous/metachronous: 26/21, number of LM: 4 ≥ / 5 ≤: 9/38. Regimens of CT were; 5FU/5FU+LV/CPT-11+5FU/CPT-11+5FU+LV/Others: 4/11/7/18/7. In all 47 pts, response rate was 53%, median survival time and 3-year survival rate were 14.6 month and 14.6%, respectively, at a median follow-up of 43.4 month. Seven of 47 (15%) could be secondarily resected after response to CT and all had R0 resection. Estimated 3-year survival rates in resected and non-resected pts were 57.1% and 0%, respectively. Prior CT before liver resection was CPT-11+5FU+LV (IFL)/CPT-11 alone: 6/1. Of the 7 resected pts, 2 pts are alive with no evidence of disease for 38 and 40 month after initiation of CT. Five of 7 pts relapsed (liver 3, liver and lung 2) and all treated with systemic CT for recurrence. Although recurrent disease is persisting, 2 of 5 are still alive for 34 and 48 month by continuing CT. Conclusions: Effective systemic CT allows some pts with unrsectable colorectal LM to be rescued by hepatic resection and provides a chance of long-term survival. No significant financial relationships to disclose.
Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure
Authors: Maximilian Mossner, Johann-Christoph Jann, Janina Wittig, Florian Nolte, Stephanie Fey, Verena Nowak, Julia Obländer, Jovita Pressler, Iris Palme, Christina Xanthopoulos, Tobias Boch, Georgia Metzgeroth, Henning Röhl, Stephanie H. Witt, Helene Dukal, Corinna Klein, Steffen Schmitt, Patrick Gelß, Uwe Platzbecker, Ekaterina Balaian, Alice Fabarius, Helmut Blum, Torsten J. Schulze, Manja Meggendorfer, Claudia Haferlach, Andreas Trumpp, Wolf-Karsten Hofmann, Hind Medyouf, Daniel Nowak
Journal: Blood (2016)
FRI0051 Comparison Between Clinical and Ultrasonographical Examination in Early Rheumatoid Arthritis Patients: Table 1.
Authors: O. Addimanda, P. Macchioni, A. Caruso, N. Possemato, M.G. Catanoso, L. Boiardi, C. Salvarani
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To stress the need of routine use of US imaging in treat to target strategies aiming to achieve remission in early rheumatoid arthritis. <h3>Methods</h3> 72 patients consecutive with early rheumatoid arthritis (ERA,50 pts) or undifferentiated arthritis (UA, 22 pts) diagnosed according to 2010 ACR/EULAR criteria were enrolled in a single center from november 2012 to June 2014. Demographic (age, gender, disease duration, body mass index - BMI-), clinical (total swollen and tender joints count, DAS28, CDAI, SDAI, Health Assessment Questionnaire, EULAR response), serological (eritrocyte sedimentation rate, C reactive protein, rheumatoid factor -RF-, antibodies anti-cyclic citrullinated peptide -CCP-) data was collected at baseline and at 6 months follow-up. Ultrasonographic (US) hand (MCP joints, PIP joints and DIP joints), wrists (intercarpic and radiocarpic joints) and feet (MTP joints, PIP and DIP joints as well as ankle joints) evaluation was performed according to OMERACT recommendations at baseline and 6 months. <h3>Results</h3> At baseline examination the mean disease duration was 15,5±7,8 weeks (min – max 4 - 24), 33/72 (45.91%) were RF positive and 32/72 (43.1%) were ACPA positive. Sixty-four patients were treated with DMARDs (62.5% MTX, 25% HCQ, 13% others) and 57 patients received corticosteroids. Ten out of 72 patients (13.9%) showed radiographic erosions at baseline evaluation. At 6 months clinical evaluation 23 pts were in remission according to DAS28 criteria, 14 pts were in low disease activity, 23 in moderate disease activity and 10 pts still in high disease activity. Comparing US evaluation in the different level of disease acitivity only joint synovial PD showed a statistical significant difference (table1). <h3>Conclusions</h3> At 6- months US joint and tendon examination of a consecutive series of patients with early RA only the presence of synovial joint PD were significantly reduced in patients with disease remission as compared to patients with more active disease. <h3>Disclosure of Interest</h3> None declared
Blood Histamine in Leukemia and Erythremia
Authors: Michael B. Shimkin, Leo Sapirstein, Franz R. Goetzl, Priscilla M. Wheeler, Nathaniel I. Berlin
Journal: JNCI Journal of the National Cancer Institute (1949)

Journal Article Blood Histamine in Leukemia and Erythremia Get access Michael B. Shimkin, Michael B. Shimkin Search for other works by this author on: Oxford Academic PubMed Google Scholar Leo Sapirstein, Leo Sapirstein Search for other works by this author on: Oxford Academic PubMed Google Scholar Franz R. Goetzl, Franz R. Goetzl Search for other works by this author on: Oxford Academic PubMed Google Scholar Priscilla M. Wheeler, Priscilla M. Wheeler Search for other works by this author on: Oxford Academic PubMed Google Scholar Nathaniel I. Berlin Nathaniel I. Berlin Laboratory of Experimental Oncology, University of California Medical School, San Francisco, and National Cancer Institute; Department of Medical Research, Permanente Foundation, Oakland, Calif., and the Division of Medical Physics, University of California, Berkeley, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 9, Issue 5-6, April-June, Pages 379–387, https://doi.org/10.1093/jnci/9.5-6.379 Published: 01 April 1949
Individual and Community Health
Authors: R SUTHERLAND
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal